Breast cancer, the most common health burden to women globally, is considered a major
cause of death for women every year. Many signal transduction pathways can cause breast cancer.
The kinase inhibitors can interrupt the signaling pathways, minimize tumor growth and consequently
cure the disease. The scientists have discovered many kinase inhibitors as targeted drugs for breast
cancer. In recent years, the inhibitors of EGFR, HER2, VEGFR, PI3K, CDK4/6, PARP and hormone
receptor have been studied well for curing breast cancer. The FDA has approved a few kinase drugs
such as trastuzumab, lapatinib, neratinib, palbociclib, abemaciclib, alpelisib to treat breast cancer recently.
In this review, we summarized the latest development of kinase inhibitors as breast cancer